Business
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD); opicapone, an investigational adjunctive treatment for Parkinson's disease (PD) in the U.S.; and VY-AADC, a gene therapy for PD acquired through a strategic collaboration with Voyager Therapeutics. The data will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders® in Nice, France, Sept. 22-26, 2019. \n\n \n\"We look forward to sharing data from our movement disorder programs in tardive dyskinesia and Parkinson's disease, including long-term data in patients with tardive dyskinesia who respond early to INGREZZA treatment and new long-term data analyses of INGREZZA at the 40 mg dose. We will also present data from our Parkinson's disease programs, including data describing the pharmacokinetics and pharmacodynamic effect of opicapone on COMT enzyme activity and levodopa concentration in patients with Parkinson's disease, as well as an analysis of Parkinson's disease progression in patients treated with the gene therapy, VY-AADC,\" said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. \"These data add to our understanding of these debilitating movement disorders that can place a substantial burden on the lives of patients.\" \nThe five abstracts that will be presented at the 2019 International Congress of Parkinson's Disease and Movement Disorders are:\nINGREZZA® (valbenazine)\nLong-Term Outcomes in Patients with Tardive Dyskinesia Who Were Early Responders with Valbenazine Abstract number: 1456; Topic: Drug-Induced Movement Disorders; Tuesday, Sept. 24 from 1:45-3:15 p.m. CEST Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive DyskinesiaAbstract number: 1464; Topic: Drug-Induced Movement Disorders; Tuesday, Sept. 24 from 1:45-3:15 p.m. CESTOpicapone\nPharmacokinetics of Opicapone and Effect on COMT and Levodopa Pharmacokinetics in Patients with Parkinson's Disease Abstract number: 143; Topic: Clinical Trials, Pharmacology and Treatment; Monday, Sept. 23 from 1:45-3:15 p.m. CEST Effect of Once-Daily Opicapone on the Pharmacokinetics of...